Furthermore, several studies have indicated that PD-L1 expression, programmed cell death-ligand 2 (PD-L2), and lymphocyte activation gene-3 (LAG-3) are associated with the therapeutic efficacy of ICI treatment for advanced RCC [7,8,9,10]. Here, LAG3 is linked to renal cell carcinoma.